As shown in Table 3, eleven studies [8, 11, 12, 15–18, 20–22, 24] reported the difference of ORR and DCR of icotinib in treating NSCLC between patients with EGFR mutations and wild type EGFR gene. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.